3M Company (3M CO) - Q1 2002 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for the period ended March 31, 2002. 3M Company, incorporated in Delaware, operates globally across six business segments: Transportation, Graphics and Safety; Health Care; Industrial; Consumer and Office; Electro and Communications; and Specialty Material. The company reported 389,347,924 shares of common stock outstanding as of the period end.
Key Financial Metrics
| Metric | Q1 2002 | Q1 2001 |
|---|---|---|
| Net Sales | $3,890 million | $4,164 million |
| Operating Income | $713 million | $737 million |
| Net Income | $452 million | $453 million |
| Diluted EPS | $1.14 | $1.13 |
| Operating Margin | 18.3% | 17.7% |
| Cash from Operations | $671 million | $715 million |
| Free Cash Flow | $510 million | $434 million |
| Total Debt | $2,875 million | $2,893 million |
| Working Capital | $2,261 million | $1,787 million |
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($161 million in Q1 2002, $281 million in Q1 2001).
Material Changes vs. Prior Period
- Sales Decline: Net sales decreased 6.6% year-over-year. Core volume declined 5.0% globally, driven by economic weakness in Europe (-7.9% core volume) and Latin America (-9.5% volume). A stronger U.S. dollar reduced worldwide sales by 2.9%.
- Segment Performance:
- Electro and Communications: Volume declined 23% due to weakness in telecom and electronics.
- Specialty Material: Volume declined 16.8% due to product phase-outs.
- Health Care: Volume grew 6.9% (including 2% from acquisitions).
- Transportation, Graphics and Safety: Volume grew 5.3% driven by automotive and respiratory products.
- Restructuring Charges: The company recorded $54 million in pre-tax restructuring charges in Q1 2002 (reducing net income by $35 million), compared to $23 million in acquisition-related costs in Q1 2001.
- Accounting Changes: Adoption of SFAS No. 142 eliminated goodwill amortization, boosting earnings by approximately 2 cents per share. Adoption of EITF 00-25 reclassified $6 million of advertising expenses to net sales for Q1 2001.
Guidance, Outlook, and Risks
- 2002 Earnings Guidance: Management expects full-year 2002 earnings to range from $4.80 to $5.10 per share, excluding non-recurring items. This range assumes a 12-cent positive impact from the cessation of goodwill amortization.
- Q2 Outlook: Earnings excluding non-recurring items are expected to be at or above the Q1 2002 result of $1.23 per share.
- Restructuring Progress: Total restructuring costs are expected to reach $750 million pre-tax. The company expects to complete manufacturing consolidations by June 30, 2002, and anticipates $300 million in savings for the full year 2002.
- Capital Allocation: Capital expenditures are expected to be $1 billion or less for 2002. The company has $2.1 billion remaining authorized for stock repurchases under a $2.5 billion program.
- Risks and Contingencies:
- Legal Proceedings: Significant exposure remains regarding breast implant litigation (154 lawsuits, 737 claimants) and respirator/mask/asbestos litigation (approx. 21,400 lawsuits, 77,000 claimants). A recent $22.5 million asbestos verdict is being appealed; no liability has been recorded pending the outcome.
- Currency: A strong U.S. dollar continues to negatively impact international sales and earnings.
- Economic Conditions: Ongoing global economic weakness poses a risk to volume growth.
Investor Verification Checklist
- Verify the impact of the $54 million restructuring charge on operating margins and the timeline for realizing the projected $300 million in annual savings.
- Monitor the status of the $22.5 million asbestos verdict and the potential for additional liabilities in the respirator/mask litigation.
- Assess the sustainability of volume growth in the Health Care and Transportation segments versus the continued decline in Electro and Communications.
- Review the company's ability to maintain the projected 32.5% effective tax rate given the cessation of goodwill amortization.
- Track the execution of the $2.1 billion remaining stock repurchase authorization and its impact on diluted share count.